- Company
- AKLIEF can be prescribed at general hospitals
- by Eo, Yun-Ho Aug 10, 2022 05:53am
- According to related industries, Galderma Korea's AKLIEF passed the Drug Committee (DC) of higher general hospitals such as Samsung Medical Center and Sinchon Severance Hospital. AKLIEF is a retinoid-based treatment that has been recommended as the primary treatment for acne, and is evaluated as an innovative treatment that can simultaneou
- Company
- Gov improvement plan may reduce patient drug access
- by Eo, Yun-Ho Aug 10, 2022 05:53am
- The focus is on lowering the price of the drug rather than improving the registration, shortening the time and effectiveness are insignificant." "There was no discussion with the consultative body. It's hard to gather opinions from the industry." The KRPIA expressed strong opposition to the government's plan to strengthen access to new drugs.
- Company
- Baxter International’s GM Dong-Wook Hyun suddenly resigns
- by Eo, Yun-Ho Aug 9, 2022 05:56am
- Dong-Wook Hyun, General Manager of Baxter International Korea, resigned. According to industry sources, Hyun submitted his letter of resignation last month and left the company. The exact reason for his resignation remains unknown. With Hyun’s resignation, Baxter is now seeking a new head, during which Kwang-hyuk Im, Vice President of
- Company
- Korean companies win first round of Entresto patent suit
- by Kim, Jin-Gu Aug 8, 2022 06:09am
- The first patent dispute over Novartis’s heart failure treatment ‘Entresto (valsartan+ sacubitril) ended with the victory of the Korean generic companies. The exclusive market approval (first generic exclusivity) that received attention is expected to be granted to 10 companies including Hanmi Pharmaceuticals, with the possibility of D
- Company
- Revised guidelines for dyslipidemia in Korea
- by Eo, Yun-Ho Aug 8, 2022 06:09am
- In the management of dyslipidemia, it is believed that drug prescriptions will be more aggressive in Korea. In April, The Korean Society of Lipid and Atherosclerosis unveiled some of the contents of the fifth edition of the 2022 dyslipidemia treatment guidelines at the Spring Conference, and will officially announce it in September. What is n
- Company
- Nabota's sales in US in 1Q of the year were 92 billion won
- by Aug 8, 2022 06:09am
- Daewoong Pharmaceutical's botulinum toxin drug Nabota broke a new quarterly sales record in North America. Sales also improved in the second quarter following the first quarter, surpassing 90 billion won in sales in the first half. Daewoong Pharmaceutical's partner Evolus announced on the 3rd (local time) that its sales of Jubo (Nabota) re
- Company
- 3rd PD-1i Jemperli to soon receive approval in Korea
- by Eo, Yun-Ho Aug 5, 2022 06:06am
- A third PD-1 inhibitor is knocking to enter the Korean market. According to industry sources, GSK Korea’s PD-1 inhibitor cancer immunotherapy ‘Jemperli (dostarlimab),’ which the company applied for approval earlier this year, may be approved within the year. If approved, Jemperli will become the third PD-1 inhibitor introduced to t
- Company
- Celltrion, applies for Phase III U.S. Targeting
- by Lee, Seok-Jun Aug 5, 2022 03:32am
- A clinical trial will be conducted so that Celltrion can alternatively prescribe CT-P17 (Yuflyma), an autoimmune disease treatment developed by itself, with the original Humira. Celltrion announced on the 1st that it recently submitted a global phase 3 to the FDA to secure interchangeability between CT-P17 and Humira. If it is designated as a
- Company
- Oncaspar changed supplier
- by Eo, Yun-Ho Aug 5, 2022 03:28am
- Oncaspar, a combination treatment for acute lymphocytic leukemia (ALL), which has been supplied by developer Servier, is forming a stable prescription maintenance environment. According to related industries, it passed the Drug Committee (DC) of the Big 5 general hospitals, including Samsung Medical Center, Seoul National University Hospital,
- Company
- Samjin, will develop new drugs with AI company in Canada
- by Lee, Seok-Jun Aug 5, 2022 03:28am
- Samjin Pharmaceutical announced on the 2nd that it has signed a joint research contract for AI new drug development with Cyclica, a Canadian artificial intelligence new drug development platform company. Through the agreement, Samjin Pharmaceutical will propose to Cyclica multiple drug targets currently under review. Cyclica is going to secur
